The Bacterial meningitis is a sickness subtle, which proves deadly in 10% of cases and might even lead to demise within a few hours. We have already discussed in the ago, to explain the symptoms and more efficient therapies nowadays we take the argument to give you fine news. A team of researchers from laboratories in Siena in the Swiss multinational Novartis has developed the initial vaccine tetravalent conjugate, able of immunizing strains C, A, Y and W135 of meningococcal (Or Neisseria meningitides), called cause of meningitis.

So distant, scientific research was made accessible Patient vaccines against pneumococcal, L ‘haemophilus b and merely the C strain of meningococcal, also given in children very little. “The fact that this vaccine protects not merely by the C strain also by A, Y, W135 – Said dr. Alberto Ugazio, president of the Italian Society of Paediatrics (SIP) – is a advantage for everybody and particularly for adolescents, because they live in communities and particularly crowded because they travel a set, which increases the risk of coming into communicate with strains yet small present from us, but frequently elsewhere “. And it is a double benefit, because it is the merely meningococcal bacterium that can trigger actual epidemics of meningitis.

As described by Rino Rappuoli, Global Head of Novartis Vaccines research, the new vaccine is intended for students who have with success finished the tenth year and is already accessible to the hospitals at a cost of 40 euro per pack. “In the short – Added Rappuoli – we hope to obtain registration of tetravalent even for small “.

Meningitis: a new meningitis vaccine

Children vaccine that is small provide for 18 months is currently organism produced at level that permit its customary extensive utilize and that can be official at U.S. center for Disease manage and Prevention announce Thursday.

Morbidity and Mortality Weekly Report, “the supply of Hib-containing vaccine is now sufficient to reinstate the on-time booster dose administration of Hib vaccine at 12-15 months for all children who completed the primary series.”

“Although supply is sufficient to reinstate the booster dose, there is currently only enough supply for limited catchup,” CDC noted.

“The information we are getting at CDC is that we are missing about 40 percent of cases,” Jackson said in November. “That’s a little worrisome because that’s 40 percent of people we don’t know if they have type b, which is the vaccine-preventable one, the one we are really worried about, or if they have something else. It makes it harder for us to see changes in Hib if there really is something going on in the population.”

“There used to be 20,000 cases a year, but the vaccine has brought it to less than 100,” Siegel said. “The numbers remain small. We’ve almost stamped this thing out with the vaccine, so don’t assume your kid is going to get it.” Via

Health News: Children Vaccinated